Vol. 3 No. 10 (2023)
Reimbursement Recommendations

Dupilumab (Dupixent)

Published October 31, 2023

Key Messages

  • CADTH recommends that Dupixent be reimbursed by public drug plans for the treatment of patients aged 6 months to younger than 12 years with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable, if certain conditions are met.
  • The CADTH Canadian Drug Expert Committee (CDEC) recommendation for Dupixent for the treatment of patients aged 12 years and older with moderate to severe AD dated February 2023 continues to apply to patients who are not included in the population evaluated in this recommendation.
  • Dupixent should only be covered to treat patients aged 6 months to younger than 12 years with moderate to severe AD who previously tried and did not experience improvement with, or are unable to use, topically applied drugs.
  • Dupixent should only be reimbursed if the patient is under the care of a dermatologist, allergist, clinical immunologist, or pediatrician who has expertise in the management of moderate to severe AD, and if the cost of Dupixent is reduced. When first prescribed, Dupixent should only be reimbursed for 6 months. Dupixent should not be used in combination with phototherapy, any immunomodulatory drugs (including biologics), or a Janus kinase (JAK) inhibitor treatment for moderate to severe AD.